Shanghai Kaibao Pharmaceutical Cash Flow Reinvestment Rate
Shanghai Kaibao Pharmaceutical cash flow reinvestment rate. Shanghai Kaibao Pharmaceutical (300039) has a Cash Flow Reinvestment Rate of 0.02x as of September 2025, reinvesting CN¥3.37 Million (capex CN¥3.37 Million ) from operating cash flow of CN¥190.98 Million. Explore Shanghai Kaibao Pharmaceutical cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Shanghai Kaibao Pharmaceutical (2006–2025)
Cash flow reinvestment rate of Shanghai Kaibao Pharmaceutical from 2006 to 2025. Historical reinvestment intensity for Shanghai Kaibao Pharmaceutical across 20 annual periods. Explore Shanghai Kaibao Pharmaceutical capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Shanghai Kaibao Pharmaceutical Cash Flow Reinvestment Rate by Year (2006–2025)
Shanghai Kaibao Pharmaceutical cash flow reinvestment rate by year from 2006 to 2025. Year-by-year capital reinvestment analysis for Shanghai Kaibao Pharmaceutical. For the full cash flow conversion analysis, see cash efficiency ratio of Shanghai Kaibao Pharmaceutical.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.56x | CN¥360.37 Million | CN¥230.74 Million | CN¥27.04 Million | ▲ +199.5% |
| 2024 | 0.52x | CN¥145.48 Million | CN¥278.95 Million | CN¥140.52 Million | ▼ -12.4% |
| 2023 | 0.60x | CN¥227.71 Million | CN¥382.66 Million | CN¥29.08 Million | ▼ -29.3% |
| 2022 | 0.84x | CN¥316.99 Million | CN¥376.42 Million | CN¥31.62 Million | ▲ +46.5% |
| 2021 | 0.57x | CN¥72.48 Million | CN¥126.08 Million | CN¥42.55 Million | ▲ +73.0% |
| 2020 | 0.33x | CN¥83.28 Million | CN¥250.65 Million | CN¥13.94 Million | ▼ -82.2% |
| 2019 | 1.86x | CN¥622.91 Million | CN¥334.09 Million | CN¥15.46 Million | ▲ +155.3% |
| 2018 | 0.73x | CN¥191.63 Million | CN¥262.36 Million | CN¥26.07 Million | ▼ -25.3% |
| 2017 | 0.98x | CN¥240.28 Million | CN¥245.76 Million | CN¥49.24 Million | ▼ -29.5% |
| 2016 | 1.39x | CN¥436.47 Million | CN¥314.88 Million | CN¥27.03 Million | ▲ +330.4% |
| 2015 | 0.32x | CN¥105.34 Million | CN¥327.08 Million | CN¥50.40 Million | ▲ +32.3% |
| 2014 | 0.24x | CN¥68.74 Million | CN¥282.38 Million | CN¥68.74 Million | ▼ -44.4% |
| 2013 | 0.44x | CN¥118.28 Million | CN¥270.23 Million | CN¥118.28 Million | ▲ +104.0% |
| 2012 | 0.21x | CN¥52.21 Million | CN¥243.32 Million | CN¥52.21 Million | ▼ -69.4% |
| 2011 | 0.70x | CN¥68.85 Million | CN¥98.31 Million | CN¥68.85 Million | ▼ -72.8% |
| 2010 | 2.58x | CN¥51.01 Million | CN¥19.79 Million | CN¥51.01 Million | ▲ +8.1% |
| 2009 | 2.38x | CN¥125.70 Million | CN¥52.74 Million | CN¥125.70 Million | ▲ +294.9% |
| 2008 | 0.60x | CN¥11.28 Million | CN¥18.70 Million | CN¥11.28 Million | ▲ +204.1% |
| 2007 | 0.20x | CN¥4.62 Million | CN¥23.27 Million | CN¥4.62 Million | ▼ -66.7% |
| 2006 | 0.60x | CN¥11.74 Million | CN¥19.70 Million | CN¥11.74 Million | — |